|
AU2002308295B2
(en)
|
2001-03-12 |
2007-08-23 |
Intercept Pharmaceuticals, Inc. |
Steroids as agonists for FXR
|
|
GB0302094D0
(en)
|
2003-01-29 |
2003-02-26 |
Pharmagene Lab Ltd |
EP4 receptor antagonists
|
|
GB0324269D0
(en)
|
2003-10-16 |
2003-11-19 |
Pharmagene Lab Ltd |
EP4 receptor antagonists
|
|
US10987362B2
(en)
|
2004-03-12 |
2021-04-27 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using FXR ligands
|
|
EP1734970B1
(en)
*
|
2004-03-12 |
2014-12-31 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using fxr ligands
|
|
ITMI20050912A1
(it)
|
2005-05-19 |
2006-11-20 |
Erregierre Spa |
Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
|
|
US7618956B2
(en)
|
2005-05-31 |
2009-11-17 |
The Gillette Company |
Reduction of hair growth
|
|
JP5081161B2
(ja)
*
|
2005-12-19 |
2012-11-21 |
スミスクライン ビーチャム コーポレーション |
ファルネソイドｘ受容体アゴニスト
|
|
CA2640476A1
(en)
*
|
2006-02-03 |
2007-08-16 |
Eli Lilly And Company |
Compounds and methods for modulating fx-receptors
|
|
BRPI0712262A2
(pt)
*
|
2006-05-24 |
2012-07-10 |
Lilly Co Eli |
agonistas de fxr
|
|
US8106077B2
(en)
|
2006-05-24 |
2012-01-31 |
Eli Lilly And Company |
Compounds and methods for modulating FXR
|
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
|
EP1894928A1
(en)
|
2006-08-29 |
2008-03-05 |
PheneX Pharmaceuticals AG |
Heterocyclic fxr binding compounds
|
|
EP1894924A1
(en)
*
|
2006-08-29 |
2008-03-05 |
Phenex Pharmaceuticals AG |
Heterocyclic FXR binding compounds
|
|
CL2007003035A1
(es)
*
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
|
AU2008209566C1
(en)
|
2007-01-19 |
2013-02-14 |
Intercept Pharmaceuticals, Inc. |
23-substituted bile acids as TGR5 modulators and methods of use thereof
|
|
WO2008157270A1
(en)
*
|
2007-06-13 |
2008-12-24 |
Smithkline Beecham Corporation |
Farnesoid x receptor agonists
|
|
CA2690406A1
(en)
*
|
2007-07-02 |
2009-01-08 |
Glaxosmithkline Llc |
Farnesoid x receptor agonists
|
|
TW200906823A
(en)
*
|
2007-07-16 |
2009-02-16 |
Lilly Co Eli |
Compounds and methods for modulating FXR
|
|
WO2009012400A2
(en)
*
|
2007-07-19 |
2009-01-22 |
University Of Southern California |
Orally administered peptides to improve or prevent hepatic fibrosis
|
|
US7902201B2
(en)
|
2007-12-04 |
2011-03-08 |
Hoffmann-La Roche Inc. |
Isoxazolo-pyrazine derivatives
|
|
US7943619B2
(en)
|
2007-12-04 |
2011-05-17 |
Hoffmann-La Roche Inc. |
Isoxazolo-pyridazine derivatives
|
|
WO2009071464A1
(en)
|
2007-12-04 |
2009-06-11 |
F. Hoffmann-La Roche Ag |
Isoxazolo-pyrazine derivatives
|
|
EP2234493A4
(en)
*
|
2007-12-21 |
2011-05-25 |
Univ Cincinnati |
THERAPEUTIC USE OF CARBOXYLESTERLIPASE INHIBITORS
|
|
EP2128158A1
(en)
|
2008-05-26 |
2009-12-02 |
Phenex Pharmaceuticals AG |
Heterocyclic cyclopropyl-substituted FXR binding compounds
|
|
EA020310B1
(ru)
|
2008-07-30 |
2014-10-30 |
Интерсепт Фармасьютикалз, Инк. |
Модуляторы рецептора tgr5 и их применение
|
|
EA022417B1
(ru)
*
|
2008-10-21 |
2015-12-30 |
Саймабэй Терапевтикс, Инк. |
Арильные агонисты рецептора gpr120 и их применение
|
|
ES2663948T3
(es)
|
2008-11-19 |
2018-04-17 |
Intercept Pharmaceuticals, Inc. |
Moduladores de TGR5 y método de uso de los mismos
|
|
TW201033201A
(en)
|
2009-02-19 |
2010-09-16 |
Hoffmann La Roche |
Isoxazole-isoxazole and isoxazole-isothiazole derivatives
|
|
US8389550B2
(en)
|
2009-02-25 |
2013-03-05 |
Hoffmann-La Roche Inc. |
Isoxazoles / O-pyridines with ethyl and ethenyl linker
|
|
US8227461B2
(en)
|
2009-04-30 |
2012-07-24 |
Hoffmann-La Roche Inc. |
Isoxazoles
|
|
WO2010127976A1
(en)
|
2009-05-05 |
2010-11-11 |
F. Hoffmann-La Roche Ag |
Isoxazole-pyridine derivatives
|
|
AU2010244552A1
(en)
|
2009-05-05 |
2011-09-29 |
F. Hoffmann-La Roche Ag |
Isoxazole-pyrazole derivatives
|
|
EP2427458B1
(en)
|
2009-05-05 |
2014-05-07 |
F.Hoffmann-La Roche Ag |
Isoxazole-pyridazine derivatives
|
|
MX2011011490A
(es)
|
2009-05-05 |
2011-11-18 |
Hoffmann La Roche |
Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos.
|
|
MX2011011484A
(es)
|
2009-05-07 |
2011-11-18 |
Hoffmann La Roche |
Derivados de isoxazol-piridina como moduladores del acido gamma-aminobutirico.
|
|
EP2289883A1
(en)
|
2009-08-19 |
2011-03-02 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
JP5855095B2
(ja)
|
2010-06-07 |
2016-02-09 |
ノボメディックス, エルエルシーNovomedix, Llc |
フラニル化合物およびその使用
|
|
CU24152B1
(es)
|
2010-12-20 |
2016-02-29 |
Irm Llc |
1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
US8785435B2
(en)
|
2011-10-20 |
2014-07-22 |
Hoffmann-La Roche Inc. |
Solid forms
|
|
US9982008B2
(en)
|
2012-06-19 |
2018-05-29 |
Intercept Pharmaceuticals, Inc. |
Preparation and uses of obeticholic acid
|
|
NZ734451A
(en)
|
2012-06-19 |
2018-12-21 |
Intercept Pharmaceuticals Inc |
Preparation, uses and solid forms of obeticholic acid
|
|
SI3043865T1
(sl)
|
2013-09-11 |
2021-04-30 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B
|
|
US10301268B2
(en)
*
|
2014-03-13 |
2019-05-28 |
The Salk Institute For Biological Studies |
Analogs of fexaramine and methods of making and using
|
|
EP3006939A1
(en)
|
2014-10-06 |
2016-04-13 |
Gilead Sciences, Inc. |
Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
|
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
EP3034501A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Hydroxy containing FXR (NR1H4) modulating compounds
|
|
EP3034499A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Novel FXR (NR1H4) modulating compounds
|
|
TWI698430B
(zh)
|
2015-02-13 |
2020-07-11 |
南北兄弟藥業投資有限公司 |
三環化合物及其在藥物中的應用
|
|
CA2981503C
(en)
|
2015-03-31 |
2023-09-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
SI3419624T1
(sl)
*
|
2016-02-22 |
2021-05-31 |
Novartis Ag |
Postopki za uporabo agonistov FXR
|
|
US10080741B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
WO2017189663A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2017189651A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2017201152A1
(en)
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2017201155A1
(en)
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
|
|
US10144729B2
(en)
|
2016-05-18 |
2018-12-04 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
|
US10772813B2
(en)
|
2016-06-03 |
2020-09-15 |
Colradel, LLC |
Compositions and methods of administering a colchicine based topical composition for the prevention of radiation fibrosis
|
|
CA2968836C
(en)
|
2016-06-13 |
2025-09-02 |
Gilead Sciences, Inc. |
FXR MODULATING COMPOUNDS (NR1H4)
|
|
NZ748641A
(en)
|
2016-06-13 |
2020-04-24 |
Gilead Sciences Inc |
Fxr (nr1h4) modulating compounds
|
|
TW201808283A
(zh)
|
2016-08-05 |
2018-03-16 |
廣東東陽光藥業有限公司 |
含氮三環化合物及其在藥物中的應用
|
|
US10414048B2
(en)
|
2016-09-14 |
2019-09-17 |
Faro Technologies, Inc. |
Noncontact safety sensor and method of operation
|
|
MX2019003790A
(es)
|
2016-10-04 |
2019-09-26 |
Enanta Pharm Inc |
Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
|
|
WO2018081285A1
(en)
|
2016-10-26 |
2018-05-03 |
Enanta Pharmaceuticals, Inc. |
Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
|
|
JP7618384B2
(ja)
|
2017-02-21 |
2025-01-21 |
ジェンフィ |
Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
|
|
SI4122464T1
(sl)
|
2017-03-28 |
2024-07-31 |
Gilead Sciences, Inc. |
Terapevtske kombinacije za zdravljenje bolezni jeter
|
|
WO2018178260A1
(en)
|
2017-03-30 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
|
|
MX394743B
(es)
*
|
2017-04-12 |
2025-03-04 |
Il Dong Pharma |
Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos
|
|
JP7264906B2
(ja)
|
2017-11-01 |
2023-04-25 |
ブリストル－マイヤーズ スクイブ カンパニー |
ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物
|
|
CN111278817B
(zh)
|
2017-11-01 |
2023-05-16 |
百时美施贵宝公司 |
作为法尼醇x受体调节剂的多环化合物
|
|
CN111630051B
(zh)
|
2017-11-01 |
2023-12-26 |
百时美施贵宝公司 |
作为法尼醇x受体调节剂的烯烃螺环化合物
|
|
US10689391B2
(en)
|
2017-12-12 |
2020-06-23 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
|
CN110128432B
(zh)
|
2018-02-02 |
2021-03-02 |
广东东阳光药业有限公司 |
含氮三环化合物及其在药物中的应用
|
|
WO2019160813A1
(en)
|
2018-02-14 |
2019-08-22 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
IT201800007265A1
(it)
*
|
2018-07-17 |
2020-01-17 |
|
Isossazoli come agonisti del recettore fxr
|
|
PT3911647T
(pt)
|
2019-01-15 |
2024-03-04 |
Gilead Sciences Inc |
Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
|
|
JP2022519906A
(ja)
|
2019-02-19 |
2022-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｆｘｒアゴニストの固体形態
|
|
WO2020231917A1
(en)
|
2019-05-13 |
2020-11-19 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2020249064A1
(en)
*
|
2019-06-14 |
2020-12-17 |
Nanjing Ruijie Pharma Co., Ltd. |
Compounds for modulating fxr
|
|
EP3999101A1
(en)
|
2019-07-18 |
2022-05-25 |
ENYO Pharma |
Method for decreasing adverse-effects of interferon
|
|
WO2021080013A1
(en)
*
|
2019-10-24 |
2021-04-29 |
Ono Pharmaceutical Co., Ltd. |
Inhibitors of trek (twik related k+ channels) channel function
|
|
WO2021108974A1
(en)
|
2019-12-03 |
2021-06-10 |
Gannex Pharma Co., Ltd |
Compounds for modulating activity of fxr and uses thereof
|
|
WO2021144330A1
(en)
|
2020-01-15 |
2021-07-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fxr agonists for treating an infection by hepatitis d virus
|
|
KR20230154806A
(ko)
|
2021-01-14 |
2023-11-09 |
엔요 파마 |
Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과
|
|
CN117320722A
(zh)
|
2021-04-28 |
2023-12-29 |
埃尼奥制药公司 |
使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
|
|
WO2023090858A1
(ko)
*
|
2021-11-17 |
2023-05-25 |
일동제약(주) |
아이속사졸 유도체의 제조 방법 및 그의 중간체
|